Immunological origin and functional properties of catalytic autoantibodies to amyloid beta peptide.
OBJECTIVE
Objectives The objectives of this study are to (1) evaluate the ability of the immune system to synthesize specific antibodies that catalyze the degradation of amyloid beta peptide (Abeta) and to (2) evaluate the prospect of developing a catalytic IVIG (CIVIG) formulation for therapy of Alzheimer's disease (AD).


CONCLUSIONS
Polyclonal autoantibodies from humans without dementia hydrolyzed Abeta specifically. The catalytic activity improved as a function of age. Patients with AD produced catalytic antibodies at increased levels. IgM-class antibodies expressed the activity at levels superior to IgGs. Production of catalytic autoantibodies appears to be an innate immunity function with adaptive improvements occurring upon Abeta overexpression, which suggests a beneficial function of the catalytic activity. The catalytic autoantibodies impeded Abeta aggregation, dissolved preformed Abeta aggregates, and inhibited Abeta cytotoxicity in tissue culture. Recombinant catalytic antibodies from a human library have been identified, validating the phenomenon of antibody-catalyzed Abeta cleavage. As a single catalyst molecule inactivates multiple Abeta molecules, catalytic antibodies may clear Abeta efficiently. IVIG did not cleave Abeta, indicating the importance of purification procedures that maintain catalytic site integrity. Traditional Abeta-binding antibodies form immune complexes that can induce inflammatory reaction and vascular dysfunction. Catalysts do not form stable immune complexes, minimizing these risks. Criteria appropriate for developing a CIVIG formulation with potential therapeutic utility are discussed, including isolation of the Abeta-specific catalytic subsets present in IgM and IgG from human blood.
Paul
Sudhir
S
Department of Pathology and Laboratory Medicine, Chemical Immunology Research Center, University of Texas-Houston Medical School, Houston, TX 77030, USA. Sudhir.Paul@uth.tmc.edu
Planque
Stephanie
S
Nishiyama
Yasuhiro
Y
D000544:Alzheimer Disease / Q000276:immunology / Q000628:therapy; D016229:Amyloid beta-Peptides / Q000276:immunology*; D017151:Antibodies, Catalytic / Q000276:immunology*; D001323:Autoantibodies / Q000276:immunology*; D001324:Autoantigens / Q000276:immunology*; D006801:Humans; D006868:Hydrolysis; D007113:Immunity, Innate; D007074:Immunoglobulin G / Q000276:immunology; D007075:Immunoglobulin M / Q000276:immunology; D016756:Immunoglobulins, Intravenous / Q000276:immunology / Q000627:therapeutic use; D018448:Models, Immunological; D010446:Peptide Fragments / Q000032:analysis
D016229:Amyloid beta-Peptides; D017151:Antibodies, Catalytic; D001323:Autoantibodies; D001324:Autoantigens; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D016756:Immunoglobulins, Intravenous; D010446:Peptide Fragments
Science. 1989 Jun 9;244(4909):1158-62
2727702
Springer Semin Immunopathol. 2005 Mar;26(4):485-503
15633014
J Biol Chem. 2010 Jan 8;285(2):1066-74
19889627
J Neurochem. 2007 Jun;101(5):1172-84
17286590
Autoimmun Rev. 2008 May;7(5):391-7
18486927
Nat Rev Immunol. 2006 Jun;6(6):465-75
16724100
AIDS Res Hum Retroviruses. 2007 Dec;23(12):1541-54
18160012
Biochemistry. 2008 Nov 25;47(47):12254-6
18956886
Exp Gerontol. 2002 Jul;37(7):943-8
12086704
J Biol Chem. 2003 May 30;278(22):20429-35
12665517
J Neurosci Res. 2006 Aug 1;84(2):434-43
16767774
Mol Immunol. 2009 Nov;47(1):87-95
19201029
J Biol Chem. 2008 Feb 22;283(8):4714-22
18086674
J Biol Chem. 2007 Dec 21;282(51):36987-97
17693400
Neurobiol Aging. 2009 Nov;30(11):1728-36
18294736
Neurobiol Aging. 2004 Sep;25(8):1023-32
15212827
Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4109-13
15743915
Clin Immunol. 2009 Oct;133(1):52-60
19604724
Neurosci Lett. 2009 Jan 16;449(3):240-5
18786612
Annu Rev Neurosci. 2008;31:175-93
18352830
Biochim Biophys Acta. 1997 Feb 27;1360(1):17-29
9061036
J Neurosci. 2007 Aug 22;27(34):9115-29
17715348
BMC Neurosci. 2007 Mar 20;8:22
17374155
Mol Biotechnol. 2007 Jun;36(2):113-22
17914190
Immunol Lett. 2006 Feb 28;103(1):8-16
16290203
Autoimmun Rev. 2008 Jun;7(6):415-20
18558354
Autoimmun Rev. 2008 Jun;7(6):440-4
18558359
J Biol Chem. 2008 Dec 26;283(52):36724-33
18974093